Camilo Colaco

ImmunoBiology

Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.

dont miss

The immunobiology of immunotherapy

Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.

EVEN MORE SEMINARS

  • Emlyn Samuel: Speaking at the Oncology Convention

    Emlyn Samuel
    Cancer Research UK

    Brexit: getting the best outcome for research and patients

  • Prof Christian Ottensmeier, MD, PhD, FRCP: Speaking at the Oncology Convention

    Prof Christian Ottensmeier, MD, PhD, FRCP

    Professor of Experimental Medicine

  • Profess Liz Ward: Speaking at the Oncology Convention

    Profess Liz Ward
    Centre for Functioning and Health Research, Metro South Hospital and Health Service, and The Univers

    Laryngectomy rehabilitation: Opportunities for improving speech pathology supports via telehealth

  • Prof Samuel Janes: Speaking at the Oncology Convention

    Prof Samuel Janes
    University College London Hospitals

    Coming soon

  • Professor Patricia Price: Speaking at the Oncology Convention

    Professor Patricia Price
    Action Radiotherapy

    Action Radiotherapy -a charity for radiotherapy patients and professionals.